Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution

• Principais autores: Maria Inês Teodoro (Autor), Alexandra Mayer (Autor), Ana da Costa Miranda (Autor), Hugo Nunes (Autor), Filipa Alves da Costa (Autor), António Lourenço (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

ABSTRACTBackground: Monotherapy with aromatase inhibitors and fulvestrant were the standard-of-care for hormone receptor-positive (HR+)/human epidermal growth factor receptor-type2 negative (HER2-) advanced breast cancer, before integration of cyclin-dependent kinase 4/6 inhibitors. Effectiveness da...